Post-Marketing Surveillance on the Long-Term Use of Prazaxa Capsules in Patients With Nonvalvular Atrial Fibrillation

Trial Profile

Post-Marketing Surveillance on the Long-Term Use of Prazaxa Capsules in Patients With Nonvalvular Atrial Fibrillation

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Dabigatran etexilate (Primary)
  • Indications Atrial fibrillation; Embolism and thrombosis
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 14 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 18 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Nov 2016.
    • 18 Oct 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top